Vera Therapeutics

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

BRISBANE, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the closing of its previously announced underwritten public offering of 9,274,194 shares of its Class A common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,209,677 shares, at a price to the public of $31.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $287.5 million.

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at a price to the public of $31.00 per share.

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

The biotech added two new executives to its ranks. Both have considerable experience in healthcare industry management.

Why Vera Therapeutics Stock Soared by 22% This Week

BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the appointments of two industry veterans to help lead the development of the company's drug programs including its late-stage product candidate, atacicept, to treat autoimmune diseases, currently in a Phase 3 clinical trial for IgA nephropathy (IgAN). The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.; and William D. Turner as Chief Development Officer, effective immediately.

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company's management team will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 7 – 11, 2024. The management team will also participate in one-on-one investor meetings.

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Vera Therapeutics is a clinical stage company that some analysts think could be worth $1 billion. The company could have an approved product for the treatment of IgA nephropathy by 2026.

This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street

The mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade

BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2023.

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Additional analysis of week 36 data from the Phase 2b ORIGIN study of atacicept demonstrating resolution of hematuria in the majority of IgAN patients.

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below:

Vera Therapeutics Scheduled to Present at November Investor Conferences

The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept's potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif.

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Vera Therapeutics focuses on autoimmune disorders. The company's lead therapy candidate, atacicept, is in a phase 3 trial.

Why Shares of Vera Therapeutics Jumped Tuesday

Vera Therapeutics is developing atacicept, a treatment for IgA nephropathy, which showed positive results in Phase 2b trials. The company has strong financials with a cash runway of over two years, but posted an increased net loss in the recent quarter. Despite inherent biotech risks, a speculative 'Buy' recommendation is given for Vera Therapeutics due to the promising drug, strong financial position, and potential to transform IgAN treatment.

Vera Therapeutics' Promising Atacicept Drug Targets IgAN

Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and financial results for the second quarter ended June 30, 2023.

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Vera Therapeutics revealed 36-week efficacy and safety findings of its Phase IIb ORIGIN clinical study of atacicept for IgAN at the 60th European Renal Association Congress. The study met its primary and secondary objectives, showing significant reductions in proteinuria and eGFR stabilization, leading to plans for a Phase III trial in June 2023. With the positive data and low valuation (after the sell-off), we believe Vera now looks like an attractive SMID-cap biotech for high-risk investors to play the red-hot IgAN space.

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target

Vera Therapeutics, Inc. is trying to develop an old molecule it licensed from Merck & Co., Inc. Trials conducted years earlier produced unimpressive results. While the company has produced some positive data, I am not convinced yet.

Vera: Repurposed Molecule Program Does Not Impress

Vera Therapeutics, Inc shares climbed 20% to $15.38 on Tuesday after the late-stage biotechnology company revealed positive trial results for atacicept, its treatment for an autoimmune disease of the kidney known as Immunoglobulin A Nephropathy (IgAN), or Berger's disease. Vera said the Phase 2b ORIGIN trial met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36.

Vera Therapeutics shares surge on positive IgAN trial results

Chinook Therapeutics

Shares of two biotech stocks are way up over the past month thanks to impressive clinical trial results for the drugs they're developing. Chinook Therapeutics has agreed to a buyout offer from Merck but the stock is still below the offered price.

2 Surging Healthcare Stocks With More Fuel in the Tank

New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

BRISBANE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it will host a post-ERA data presentation on Tuesday, June 20, 2023 at 8:00 AM ET.

News for Vera Therapeutics Stock (VERA)